Interpellative sociology of pharmaceuticals: Problems and challenges for innovation and regulation in the 21st century

Technology Analysis and Strategic Management

Volumn 19, Issue 3, 2007, Pages 387-402

  Abraham, John ^a   Davis, Courtney ^a  

^a UNIVERSITY OF SUSSEX   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

DECISION MAKING; DRUG DEVELOPMENT; INDUSTRIAL REGULATION; INNOVATION; PHARMACEUTICAL INDUSTRY; SAFETY; STANDARD (REGULATION); TWENTY FIRST CENTURY;

EID: 34249275710     PISSN: 09537325     EISSN: 14653990     Source Type: Journal    
DOI: 10.1080/09537320701281607     Document Type: Article

References (77)

1. The main focus of this article is drugs that are developed for use as prescription medicines.
2. J. Abraham & J. Sheppard, International comparative analysis and explanation in medical sociology: Demystifying the Halcion anomaly, Sociology, 32, 1998, pp. 141-62;
3. A. Daemmrich, Pharmacopolitics: Drug Regulation in the United States and Germany (Chapel Hill, NC, University of North Carolina Press, 2004);
4. J. Gabe & M. Bury, Halcion nights: A sociological account of a medical controversy, Sociology, 30, 1996, pp. 447-469;
5. A. Petryna, A. Lakoff & A. Kleinman (Eds), Global Pharmaceuticals: Ethics, Markets, Practices (Durham, NC, Duke University Press, 2006);
6. S. Sismondo (Ed.), Intersections of Pharmaceutical Research and Marketing: Special Issue, Social Studies of Science, 34(2), 2004.
7. C. Freeman, The Economics of Industrial Innovation (London, Pinter, 1982);
8. F. Jevons, WhoWins from Innovation?, Technology Analysis & Strategic Management, 4, 1992, pp. 399-412.
9. R.Vos, Drugs Looking for Diseases: Innovative Drug Research and the Development of the Beta Blockers (Dordrecht, Kluwer, 1991).
10. J. Abraham & T. Reed, Progress, innovation and regulatory science in drug development, Social Studies of Science, 32, 2002, pp. 337-369.
11. J. Abraham, Pharmaceuticals, the state and the global harmonisation process, Australian Health Review, 28, 2004, pp. 150-161;
12. J. Abraham & G. Lewis, Regulating Medicines in Europe: Competition, Expertise and Public Health (London, Routledge, 2000).
13. International Society of Drug Bulletins, ISDB Declaration on Therapeutic Advance in the Use of Medicines, Paris, 15-16 November 2001.
14. House of Commons, Inquiry into the influence of the pharmaceutical industry, Health Select Committee Report, 2005.
15. House of Commons, Inquiry into the influence of the pharmaceutical industry, Health Select Committee Hearing, 20 January 2005, Evidence 354-356.
16. K. I. Kaitin & J. Di Masi, Measuring the pace of new drug development in the user fee era, Drug Information Journal, 24, 2000, pp. 673-680.
17. D. A. Kessler, A. E. Hass, K. L. Feiden, M. Lumpkin & R. Temple, Approval of new drugs in the US: Comparison with the UK, Germany and Japan, Journal of the American Medical Association, 276, 1996, pp. 1826-1831.
18. Abraham & Lewis, op. cit., Ref. 6, p. 20.
19. J. Abraham, The political economy of medicines regulation in Britain, in: H. LawtonSmith (Ed.) The Regulation of Science and Technology (Basingstoke, UK, Palgrave, 2002), pp. 221-263.
20. H. Grabowski, J. Vernon & L. Thomas, Estimating the effects of regulation on innovation: An international comparative analysis of the pharmaceutical industry, Journal of Law and Economics, 21, 1978, pp. 133-163;
21. W. Wardell, Introduction of new therapeutic drugs in the US and Great Britain: An international comparison, Clinical Pharmacology and Therapeutics, 14, 1973, pp. 773-790.
22. F. Andersson, The drug lag issue: The debate seen from an international perspective, International Journal of Health Services, 22, 1992, pp. 62-68.
23. Anon, New license fees proposed, Scrip, 1369, 1988, p. 8.
24. S. O. Schweitzer, M. E. Schweitzer & M.-J. Sourty-Le Guellec, Is there a US drug lag? The timing of new pharmaceutical approvals in the G-7 countries and Switzerland, Medical Care Research and Review, 53, 1996, pp. 162-178.
25. Me-toos are NMEs, but they are very minor molecular modifications of existing drugs within the same therapeutic class and often offer little or no therapeutic advance on existing drugs.
26. S. Chapman, P. Durieux & T. Walley, Good prescribing practice, in: E. Mossialos, M. Mrazek & T. Walley (Eds) Regulating Pharmaceuticals in Europe: Striving for Efficiency, Equity and Quality (Milton Keynes, UK, Open University Press, 2004), pp. 144-157.
27. M. Angell, The Truth about Drug Companies (NewYork, Random House, 2004).
28. A. McIntyre, Key Issues in the Pharmaceutical Industry (Chichester, UK, John Wiley, 1999), pp. 17-19.
29. R. G. Halliday, A. L. Drasdo, C. E. Lumley & S. R. Walker, The allocation of resources for R&D in the world's leading pharmaceutical companies, R&D Management, 27, 1997, p. 63
30. I. P. Tansey, N. A. Armstrong & S. R. Walker, Trends in pharmaceutical innovation: The introduction of products on to the UK market, 1960-1989, Journal of Pharmaceutical Medicine, 4, 1994, p. 85.
31. McIntyre, op. cit., Ref. 20, p. 96.
32. H. Nakajima, The ICH programme: Accomplishments and impact on world health, in: P. F. D'Arcy & D. W. G. Harron (Eds) Proceedings of the Third International Conference on Harmonisation (Belfast, IFPMA, 1999), p. 32.
33. M. Bangemann,Welcome and introduction: Welcome address by Mr Martin Bangemann, Vice-President of the Commission of the European Communities, in: P. F. D'Arcy & D.W. G. Harron (Eds) Proceedings of the First International Conference on Harmonisation (Belfast, IFPMA, 1992), p. 4.
34. IFPMA, The Value and Benefits of ICH to Industry (Geneva, IFPMA, 2000), p. 1.
35. It is theoretically possible that ICH has provided such benefits, but they have been overwhelmed by other anti-innovation factors. However, this view could easily be wishful thinking about the consequences of ICH as it has no evidential basis.
36. Anon, ICH2 - status of tripartite harmonisation initiatives, Scrip, 1872, 1993, p. 19.
37. J. S. Brown, K. I. Kaitin, N. McAuslane, K. E. Thomas & S. R. Walker, Population exposure required to assess clinical safety: Report to the ICH Working Group, Drug Information Journal, 30, 1996, pp. 17-27.
38. R. J. Garutti, Clinical safety data management: Definitions and standards for expedited reporting, in: P. F. D'Arcy & D. W. G. Harron (Eds) Proceedings of the Second International Conference on Harmonisation (Belfast, IFPMA, 1994), p. 376.
39. A. J. Gordon, Clinical safety data management: ICH guideline - recommendations and reasoning, in: P. F. D'Arcy & D. W. G. Harron (Eds) Proceedings of the Second International Conference on Harmonisation (Belfast, IFPMA, 1994), p. 384.
40. J. Abraham, Negotiation and accommodation in expert medical risk assessment and regulation: An institutional analysis of the Benoxaprofen case, Policy Sciences, 27, 1994, pp. 53-76.
41. J.Abraham, Distributing the benefit of the doubt: Scientists, regulators and drug safety, Science, Technology & Human Values, 19, 1994, pp. 493-522.
42. J. Abraham & C. Davis, Testing times: The emergence of the Practolol disaster and its challenge to British drug regulation in the modern period, Social History of Medicine, 17, 2006, pp. 1-21.
43. Code of Federal Regulations, CFR Part 314, Subpart H (Accelerated Approval of New Drugs for Serious or Life-Threatening Illnesses, 1992).
44. T. G. Roberts & B.A. Chabner, Beyond fast track for drug approvals, New England Journal of Medicine, 351, 2004, p. 502.
45. FDA, Modernisation Act, Section 506(b)(3) of the Food, Drug and Cosmetic Act (as amended by Section 112 of FDAMA, 1997).
46. Official Journal of the European Union, OJ L 136 30.4.2004 Of the European Parliament and the Council,
47. March 2004. Laying down Community procedures for the authorisation and supervision of medicinal products for human and veterinary use and for establishing a European Medicines Agency, 2004, para 33.
48. S. Garattini & V. Bertele, Adjusting Europe's drug regulation to public health needs, Lancet, 358, 2001, p. 66.
49. House of Commons, Inquiry into the influence of the pharmaceutical industry, Health Select Committee Hearing, 13 January 2005, Evidence 298.
50. E. A. M. Gale, Lessons from the glitazones, Lancet, 357, 2001, p. 1871.
51. In 2004 the CPMP changed its name to the Committee for Human Medicinal Products (CHMP).
52. Interview with former member of CPMP, 20 January 2005.
53. Roberts & Chabner, op. cit., Ref. 34.
54. T. R. Fleming, Surrogate endpoints and FDA's accelerated approval process, Health Affairs, 24, 2005, pp. 67-78.
55. M. Mitka,Acclererated approval scrutinized - confirmatory phase 4 studies on newdrugs languid, Journal of the American Medical Association, 289, 2003, pp. 3227-3229.
56. House of Commons, op. cit., Ref. 8, p. 75.
57. J. Abraham & J. Sheppard, The Therapeutic Nightmare: The Battle over the World's Most Controversial Sleeping Pill (London, Earthscan, 1999).
58. J. Abraham & G. Lewis, Citizenship, medical expertise and the capitalist regulatory state, Sociology, 36, 2002, pp. 67-88.
59. ABPI, Dr John Griffin takes over as ABPI Chief, ABPI News, 198, 1984, p. 1;
60. J. Braithwaite, Corporate Crime in the Pharmaceutical Industry (London, Routledge & Kegan Paul, 1986), p. 298;
61. T. Delamothe, Drugs watchdogs and the drug industry, British Medical Journal, 299, 1989, p. 476;
62. L. Hancher & M. Moran, Conclusion: Organising regulatory space, in: L. Hancher & M. Moran (Eds) Capitalism, Culture and Economic Regulation (Oxford, Clarendon, 1989), p. 288.
63. Abraham & Lewis, op. cit., Ref. 6; M. M. Atkinson & W. D. Coleman, Corporatism and industrial policy, in: A. Cawson (Ed.) Organised Interests and the State (London, Sage, 1985), pp. 22-44
64. M. Bernstein, Regulating Business by Independent Commission (Princeton, NJ, Princeton University Press, 1955).
65. J. Abraham & G. Lewis, Europeanization of medicines regulation, in: J. Abraham & H. LawtonSmith (Eds) Regulation of the Pharmaceutical Industry (Basingstoke, UK, Palgrave, 2003), pp. 42-81.
66. Anon, US FDA/NCI Reconcile Differences? Scrip, 1450, 1989, p. 20.
67. P. J. Hilts, Protecting America's Health: The FDA, Business and One Hundred Years of Regulation (New York, Knopf, 2003), p. 255.
68. D. P. Carpenter, The political economy of FDA drug review: Processing, politics and lessons for policy, Health Affairs, 23, 2004, pp. 52-63;
69. A. Daemmrich & G. Krucken, Risk versus risk: Decision-making dilemmas of drug regulation in the US and Germany, Science as Culture, 9, 2000, pp. 505-534. 54.
70. FDA, op. cit., Ref. 35.
71. J. Abraham, Science, Politics and the Pharmaceutical Industry: Controversy and Bias in Drug Regulation (NewYork: UCL/St Martin's Press, 1995).
72. Abraham & Lewis, op. cit., Ref. 6.
73. J. Abraham & G. Lewis, Secrecy and transparency of medicines licensing in the EU, Lancet 352, 1998, pp. 480-482.
74. Hilts, op. cit., Ref. 52, pp. 195-197;
75. S. Jasanoff, The Fifth Branch: Science Advisers as Policymakers (Cambridge, MA, Harvard University Press, 1990), p. 247.
76. J. Abraham & C. Davis, A comparative analysis of drug safety withdrawals in the UK and the US (1971-1992): Implications for current regulatory thinking and policy, Social Science & Medicine, 61, 2005, pp. 881-892.
77. House of Commons, op. cit., Ref. 8, p. 52.